BKM120 (NVP-BKM120, Buparlisib) Chemical Properties

Melting point:

143-147°C

Boiling point:

645.7±65.0 °C(Predicted)

Density 

1.382

storage temp. 

-20°C

solubility 

Soluble in DMSO (15 mg/ml)

form 

White powder.

pka

5.94±0.50(Predicted)

color 

White

Stability:

Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Safety Information

HS Code 

29349990

BKM120 (NVP-BKM120, Buparlisib) Usage And Synthesis

Description

Buparlisib (944396-07-0) is potent pan-Class I PI3-kinase inhibitor (IC50’s: p110α = 52 nM, p110? = 166 nM, p110δ = 116 nM. P110g = 262 nM).1,2 It inhibited microtubule dynamics at in vitro concentrations >1μM and doses above 50mg/kg in mice.3 Buparlisib lead to a precipitous drop in DNA synthesis in a mouse model of BRCA1-linked triple-negative breast cancer with less affect in normal tissue.4

Uses

A selective Class I PI3K inhibitor of p110α, p110β, p110δ and p110γ with IC50s of 50-300 nM.

Uses

NVP-BKM 120 is a novel anti-tumor active compound that is selective in that it inhibits specifically PI3 kinase activating cell death in glioma cells. Glioma cells being those that proliferate from tumors in the brain or the spine.

Definition

ChEBI: BKM120 is an aminopyridine that is 4-(trifluoromethyl)pyridin-2-amine substituted at position 5 by a 2,6-di(morpholin-4-yl)pyrimidin-4-y group. A selective PI3K inhibitor with anti-tumour properties. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and an antineoplastic agent. It is a member of morpholines, an aminopyrimidine, an aminopyridine and an organofluorine compound.

in vivo

target

p110α

IC 50

p110α: 52 nM (IC₅₀); p110α-H1047R: 58 nM (IC₅₀); p110α-E545K: 99 nM (IC₅₀); p110δ: 116 nM (IC₅₀); p110β: 166 nM (IC₅₀); p110γ: 262 nM (IC₅₀); Vps34: 2.4 μM (IC₅₀); mTOR: 4.6 μM (IC₅₀)

References

[1] MATTHEW T. BURGER*. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer[J]. ACS Medicinal Chemistry Letters, 2011, 2 10: 774-779. DOI:10.1021/ml200156t
[2] SAUVEUR-MICHEL MAIRA. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.[J]. Molecular Cancer Therapeutics, 2012, 11 2: 317-328. DOI:10.1158/1535-7163.mct-11-0474
[3] SASKIA M BRACHMANN. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.[J]. Molecular Cancer Therapeutics, 2012, 11 8: 1747-1757. DOI:10.1158/1535-7163.mct-11-1021
[4] ASHISH JUVEKAR. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113 30: E4338-47. DOI:10.1073/pnas.1522223113

BKM120 (NVP-BKM120, Buparlisib)(944396-07-0)Related Product Information

• Epacadostat (INCB024360)
• Nintedanib Ethanesulfonate Salt
• AnaMorelin hydrochloride
• Niraparib tosylate
• MK-4827 (tosylate)
• Everolimus
• MK-2206 2HCl
• Alpelisib (BYL719)
• Pictilisib
• CAL-101
• BEZ235 (NVP-BEZ235, Dactolisib)
• Ruxolitinib phosphate
• R428
• Nutlin 3a
• 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
• 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide
• BMS-794833
• EGF816 (mesylate)